Document Detail

Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy.
MedLine Citation:
PMID:  22271898     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Outcomes in chronic myeloid leukemia have improved with tyrosine kinase inhibitor treatment. However, little is known about outcomes of chronic myeloid leukemia in adolescent and young adult patients.
DESIGN AND METHODS: We reviewed all 468 chronic myeloid leukemia patients treated at our institution with tyrosine kinase inhibitors as initial therapy: imatinib (n=281), nilotinib (n=98) or dasatinib (n=89).
RESULTS: Median age was 47 years, median follow up 71 months and median treatment time with initial tyrosine kinase inhibitors 48 months. Adolescent and young adult was defined as aged 15-29 years. Sixty-one adolescent and young adult patients were identified. The only significant differences between adolescent and young adult and older patients were incidence of splenomegaly and distribution in Sokal risk groups. Only 3 adolescent and young adult patients have died. Rates of complete cytogenetic, major molecular and complete molecular response were significantly higher in older patients compared to adolescent and young adult patients, with a favorable trend in event-free survival for older patients. Transformation-free and overall survival were similar for the two groups.
CONCLUSIONS: The unfavorable trend in outcome for adolescent and young adult patients with chronic myeloid leukemia is unexpected. Additional research in this population is required to better define outcomes, understand the cause of this difference, and to help make better treatment recommendations.
Naveen Pemmaraju; Hagop Kantarjian; Jianqin Shan; Elias Jabbour; Alfonso Quintas-Cardama; Srdan Verstovsek; Farhad Ravandi; William Wierda; Susan O'Brien; Jorge Cortes
Related Documents :
17895058 - A systematic review of randomized evidence for fibrinogen-depleting agents in acute isc...
18347278 - Efficacy and safety of recombinant activated factor vii in major surgical procedures: s...
18400878 - The use of prolotherapy in the sacroiliac joint.
18631428 - Examining the evidence: complementary adjunctive therapies for multiple sclerosis.
11786318 - Intraluminal 192ir brachytherapy following transjugular intrahepatic portosystemic shun...
12453138 - Debridement performance index and its correlation with complete closure of diabetic foo...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, N.I.H., Extramural     Date:  2012-01-22
Journal Detail:
Title:  Haematologica     Volume:  97     ISSN:  1592-8721     ISO Abbreviation:  Haematologica     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-07-16     Completed Date:  2012-12-31     Revised Date:  2013-12-09    
Medline Journal Info:
Nlm Unique ID:  0417435     Medline TA:  Haematologica     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  1029-35     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Age Factors
Aged, 80 and over
Antineoplastic Agents / administration & dosage*
Drug Administration Schedule
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis,  drug therapy*,  mortality
Middle Aged
Neoplasm Proteins / antagonists & inhibitors,  metabolism
Piperazines / administration & dosage*
Protein Kinase Inhibitors / administration & dosage*
Protein-Tyrosine Kinases / antagonists & inhibitors,  metabolism
Pyrimidines / administration & dosage*
Survival Rate
Thiazoles / administration & dosage*
Treatment Outcome
Grant Support
Reg. No./Substance:
0/4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide; 0/Antineoplastic Agents; 0/Benzamides; 0/Neoplasm Proteins; 0/Piperazines; 0/Protein Kinase Inhibitors; 0/Pyrimidines; 0/Thiazoles; BKJ8M8G5HI/imatinib; EC Kinases; RBZ1571X5H/dasatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inh...
Next Document:  Endoglin expression level discriminates long-term hematopoietic from short-term clonogenic progenito...